Generic Nesina Availability
Last updated on Sep 10, 2026.
Nesina is a brand name of alogliptin, approved by the FDA in the following formulation:
| Manufacturer | Approval date | Strengths [RLD] |
|---|---|---|
| TAKEDA PHARMS USA | January 25, 2013 |
|
Has a generic version of Nesina been approved?
Yes, the following Nesina generics have been approved by the FDA:
Authorized generic versions| Company | NDC Code Number | Formulation |
|---|---|---|
| Padagis Israel Pharmaceuticals Ltd | 458020087 |
Alogliptin ORAL TABLET, FILM COATED 6.25 mg |
| Padagis Israel Pharmaceuticals Ltd | 458020103 |
Alogliptin ORAL TABLET, FILM COATED 12.5 mg |
| Padagis Israel Pharmaceuticals Ltd | 458020150 |
Alogliptin ORAL TABLET, FILM COATED 25 mg |
| A-S Medication Solutions | 500905574 |
Alogliptin ORAL TABLET, FILM COATED 25 mg |
| Bryant Ranch Prepack | 636294946 |
Alogliptin ORAL TABLET, FILM COATED 25 mg |
| Aphena Pharma Solutions - Tennessee, LLC | 716100300 |
Alogliptin ORAL TABLET, FILM COATED 25 mg |
| Aphena Pharma Solutions - Tennessee, LLC | 716100661 |
Alogliptin ORAL TABLET, FILM COATED 12.5 mg |
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nesina. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Generic Nesina prices
Pricing information is not currently available. While the medication may be approved, it does not appear to be commercially available at this time. Market launch delays can occur. For the most accurate and up-to-date information, consider contacting the manufacturer.
Patent protection
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development. These patents may include claims related to the drug's formulation, manufacturing process, or other aspects.
| Patent Title | Dipeptidyl peptidase inhibitors |
|---|---|
| Patent Number | 7,807,689 |
| Issue Date | October 5, 2010 |
| Inventor | Zhang; Zhiyuan & Elder; Bruce J. & Isbester; Paul K. & Palmer; Grant J. & Ulysse; Luckner G. |
| Current Assignee | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Patent Description |
The present invention provides a compound of the formula: or stereoisomers or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, articles of manufacture comprising the same, and methods of using the same.
|
| Patent Expiry Dates |
June 27, 2028
Patent Use: METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN Drug Substance: Yes Drug Product: Yes |
| Patent Title | Tablet preparation without causing a tableting trouble |
|---|---|
| Patent Number | 8,697,125 |
| Issue Date | April 15, 2014 |
| Inventor | Ono Akihiko & Marunaka Shigeyuki & Fukuta Makoto |
| Current Assignee | Takeda Pharmaceutical Company Limited |
| Patent Description |
The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.
|
| Patent Expiry Dates |
June 16, 2029
Drug Product: Yes |
FDA exclusivity
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
| Expiration Date | Description |
|---|---|
| July 27, 2026 | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST |
More about Nesina (alogliptin)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: dipeptidyl peptidase 4 inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
